Assembly Biosciences, Inc. ASMB
Biotechnology: Pharmaceutical Preparations · IPO 2010 · data as of November 13, 2026
Assembly Biosciences, Inc. (ASMB) is a healthcare company listed in the US with a market value of about $432M. In fiscal year 2025 it had revenue of $72M and net income of -$6M, a net margin of -8.5%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 28.2, 5-year revenue growth of -2% a year, a 5-year average ROIC of -81%.
About Assembly Biosciences
Assembly Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2010. Revenue went from $9M in 2017 to $72M in 2025, growth of about 29.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 178% over three years (dilution for shareholders). It spends 90% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $29M | $7M | $0 | $6M | $79M | $16M | $15M | $9M | $0 |
| Net income | -$6M | -$40M | -$61M | -$93M | -$130M | -$62M | -$98M | -$91M | -$43M | -$44M |
| Free cash flow | -$41M | -$51M | $22M | -$85M | -$96M | -$63M | -$86M | -$65M | $995000 | -$35M |
| EPS (diluted) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-36.00 | $-21.00 | $-44.64 | $-47.76 | $-28.92 | $-30.84 |
| Net margin | -8.5% | -140.9% | -854.8% | — | -2076.3% | -78.6% | -611.6% | -613.0% | -474.7% | — |
| ROIC | -5.8% | -98.5% | -117.6% | -109.3% | -74.2% | -25.8% | -35.7% | -32.6% | -38.1% | -55.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $51.20, 142% above the current price; targets range from $43.00 to $62.00; the consensus rating is “Strong buy”; expected EPS is $-0.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Assembly Biosciences’s P/E ratio?
About 28.2, based on the last twelve months of diluted earnings per share.
Does Assembly Biosciences pay a dividend?
Not currently.
Is Assembly Biosciences a good stock to buy?
We do not give buy or sell advice. Assembly Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.